Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

We observed pronounced increases in 25OHD levels after 4 months in the active arm (median 32.9 ng/mL; IQ range 25.9 to 38.4) against placebo (median 19.05 ng/mL; IQ range 13.0 to 25.9), constantly rising during treatment.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Other blinding reported · Human research reported

Reported blinded roles: participants.

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Study participants were 104 adults aged 75 years or younger with recent resected stage II cutaneous malignant melanoma.

Source: Methods.

Both participants and clinicians were blinded as to the treatment arm.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Vitamin D Supplementation and Disease-Free Survival in Stage II Melanoma: A Randomized Placebo Controlled Trial

Study design awaiting verification · Nutrients · 2021

Original publication title

Vitamin D Supplementation and Disease-Free Survival in Stage II Melanoma: A Randomized Placebo Controlled Trial

Harriet Johansson; Giuseppe Spadola; Giulio Tosti; Mario Mandalà; Alessandro M. Minisini; Paola Queirolo; Valentina Aristarco; Federica Baldini; Emilia Cocorocchio; Elena Albertazzi; Leonardo Zichichi; Saverio Cinieri; Costantino Jemos; Giovanni Mazzarol; Patrizia Gnagnarella; Debora Macis; Ines Tedeschi; Emanuela Omodeo Salè; Luigia Stefania Stucci; Bernardo Bonanni; Alessandro Testori; Elisabetta Pennacchioli; Pier Francesco Ferrucci; Sara Gandini; on behalf of the Italian Melanoma Intergroup (IMI)

© 2021 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Patients with newly resected stage II melanoma (n = 104) were randomized to receive adjuvant vitamin D3 (100,000 IU every 50 days) or placebo for 3 years to investigate vitamin D3 protective effects on developing a recurrent disease. Median age at diagnosis was 50 years, and 43% of the patients were female. Median serum 25-hydroxy vitamin D (25OHD) level at baseline was 18 ng/mL, interquartile range (IQ) was 13 to 24 ng/mL, and 80% of the patients had insufficient vitamin D levels.

We observed pronounced increases in 25OHD levels after 4 months in the active arm (median 32.9 ng/mL; IQ range 25.9 to 38.4) against placebo (median 19.05 ng/mL; IQ range 13.0 to 25.9), constantly rising during treatment. Remarkably, patients with low Breslow score (<3 mm) had a double increase in 25OHD levels from baseline, whereas patients with Breslow score ≥3 mm had a significantly lower increase over time. After 12 months, subjects with low 25OHD levels and Breslow score ≥3 mm had shorter disease-free survival (p = 0.02) compared to those with Breslow score <3 mm and/or high levels of 25OHD.

Adjusting for age and treatment arm, the hazard ratio for relapse was 4.81 (95% CI: 1.44 to 16.09, p = 0.011). Despite the evidence of a role of 25OHD in melanoma prognosis, larger trials with vitamin D supplementation involving subjects with melanoma are needed.

Authors’ abstract

Patients with newly resected stage II melanoma (n = 104) were randomized to receive adjuvant vitamin D3 (100,000 IU every 50 days) or placebo for 3 years to investigate vitamin D3 protective effects on developing a recurrent disease. Median age at diagnosis was 50 years, and 43% of the patients were female. Median serum 25-hydroxy vitamin D (25OHD) level at baseline was 18 ng/mL, interquartile range (IQ) was 13 to 24 ng/mL, and 80% of the patients had insufficient vitamin D levels.

We observed pronounced increases in 25OHD levels after 4 months in the active arm (median 32.9 ng/mL; IQ range 25.9 to 38.4) against placebo (median 19.05 ng/mL; IQ range 13.0 to 25.9), constantly rising during treatment. Remarkably, patients with low Breslow score (<3 mm) had a double increase in 25OHD levels from baseline, whereas patients with Breslow score ≥3 mm had a significantly lower increase over time. After 12 months, subjects with low 25OHD levels and Breslow score ≥3 mm had shorter disease-free survival (p = 0.02) compared to those with Breslow score <3 mm and/or high levels of 25OHD.

Adjusting for age and treatment arm, the hazard ratio for relapse was 4.81 (95% CI: 1.44 to 16.09, p = 0.011). Despite the evidence of a role of 25OHD in melanoma prognosis, larger trials with vitamin D supplementation involving subjects with melanoma are needed.

Publication and source details

Original title: Vitamin D Supplementation and Disease-Free Survival in Stage II Melanoma: A Randomized Placebo Controlled Trial

Harriet Johansson; Giuseppe Spadola; Giulio Tosti; Mario Mandalà; Alessandro M. Minisini; Paola Queirolo; Valentina Aristarco; Federica Baldini; Emilia Cocorocchio; Elena Albertazzi; Leonardo Zichichi; Saverio Cinieri; Costantino Jemos; Giovanni Mazzarol; Patrizia Gnagnarella; Debora Macis; Ines Tedeschi; Emanuela Omodeo Salè; Luigia Stefania Stucci; Bernardo Bonanni; Alessandro Testori; Elisabetta Pennacchioli; Pier Francesco Ferrucci; Sara Gandini; on behalf of the Italian Melanoma Intergroup (IMI)

Nutrients · 2021

* Correspondence: harriet.johansson@ieo.it; Tel.: +39-0294372654
†

Member of the Italian Melanoma Intergroup (IMI), 16121 Genoa, Italy; segreteria.melanomaimi@gmail.com. Additional information is provided in the Acknowledgments.

© 2021 by the authors.2021https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T13:16:50.945946+00:00

DOI: 10.3390/nu13061931 · PMC8226808